AstraZeneca's immune disorder drug succeeds in late-stage trial
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised mya...
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Pr...
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom o...
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is annou...
AstraZeneca announces $50bn US investment in manufacturing and R&D
AstraZeneca PLC (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, marking its largest-ever commitment to a single country and signalling a major boost for domestic dr...
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. Th...
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Pr...
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
AstraZeneca drug lowers high BP in late-stage study; shares rise
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugm...
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pip...
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5....
Related Companies